Drug Trial Radar · NCT02382939
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Feb 12, 2015
Primary completion
Jan 4, 2016
Study completion Jan 4, 2016
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily Norditropin® FlexPro® (somatropin delivered within a prefilled pen) for 26 weeks in previously human growth hormone (hGH) treated adults with growth hormone deficiency.
Conditions
- Adult Growth Hormone Deficiency
- Growth Hormone Disorder
Interventions
somapacitanDrug
Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
somatropinDrug
Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Weeks 0 - 26
- Incidence of Injection Site ReactionsTime frame: Weeks 0- 26
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Århus C, Denmark
Novo Nordisk Investigational Site
København Ø, Denmark
Novo Nordisk Investigational Site
Odense, Denmark
Novo Nordisk Investigational Site
Angers, France
Novo Nordisk Investigational Site
Brest, France
Novo Nordisk Investigational Site
Bron, France
Novo Nordisk Investigational Site
Dijon, France
Novo Nordisk Investigational Site
Saint-Herblain, France
Novo Nordisk Investigational Site
Aachen, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Frankfurt, Germany
Novo Nordisk Investigational Site
Bunkyo-ku, Tokyo, Japan
Novo Nordisk Investigational Site
Itabashi-ku, Tokyo, Japan
Novo Nordisk Investigational Site
Izumo, Shimane, Japan
Novo Nordisk Investigational Site
Kobe-shi, Hyogo, Japan
Novo Nordisk Investigational Site
Kobe, Hyogo, Japan
Novo Nordisk Investigational Site
Kyoto-shi Kyoto, Japan
Novo Nordisk Investigational Site
Okayama, Okayama, Japan
Novo Nordisk Investigational Site
Sagamihara-shi, Kanagawa, Japan
Novo Nordisk Investigational Site
Gothenburg, Sweden
Novo Nordisk Investigational Site
Lund, Sweden
Novo Nordisk Investigational Site
Stockholm, Sweden
Novo Nordisk Investigational Site
Birmingham, United Kingdom
Novo Nordisk Investigational Site
Exeter, United Kingdom
Novo Nordisk Investigational Site
Leeds, United Kingdom
Novo Nordisk Investigational Site
London, United Kingdom
Novo Nordisk Investigational Site
London, United Kingdom
Novo Nordisk Investigational Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.